These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16136028)

  • 21. Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.
    Horton TM; Thompson PA; Berg SL; Adamson PC; Ingle AM; Dolan ME; Delaney SM; Hedge M; Weiss HL; Wu MF; Blaney SM;
    J Clin Oncol; 2007 Nov; 25(31):4922-8. PubMed ID: 17971589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
    Gander M; Leyvraz S; Decosterd L; Bonfanti M; Marzolini C; Shen F; Liénard D; Perey L; Colella G; Biollaz J; Lejeune F; Yarosh D; Belanich M; D'Incalci M
    Ann Oncol; 1999 Jul; 10(7):831-8. PubMed ID: 10470431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
    Loghin ME; Prados MD; Wen P; Junck L; Lieberman F; Fine H; Fink KL; Metha M; Kuhn J; Lamborn K; Chang SM; Cloughesy T; DeAngelis LM; Robins IH; Aldape KD; Yung WK
    Clin Cancer Res; 2007 Dec; 13(23):7133-8. PubMed ID: 18056194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
    Wagner LM; Perentesis JP; Reid JM; Ames MM; Safgren SL; Nelson MD; Ingle AM; Blaney SM; Adamson PC
    Pediatr Blood Cancer; 2010 Apr; 54(4):538-45. PubMed ID: 20049936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temozolomide and cisplatin in relapsed/refractory acute leukemia.
    Seiter K; Katragadda S; Ponce D; Rasul M; Ahmed N
    J Hematol Oncol; 2009 May; 2():21. PubMed ID: 19463179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers.
    Awada A; Gil T; Sales F; Dubuisson M; Vereecken P; Klastersky J; Moerman C; de Valeriola D; Piccart MJ
    Anticancer Drugs; 2004 Jun; 15(5):499-502. PubMed ID: 15166625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
    Jones SF; Gian VG; Greco FA; Miranda FT; Shipley DL; Thompson DS; Hainsworth JD; Toomey MA; Willcutt NT; Burris HA
    Oncology (Williston Park); 2003 May; 17(5 Suppl 5):41-5. PubMed ID: 12800606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
    Brandes AA; Basso U; Reni M; Vastola F; Tosoni A; Cavallo G; Scopece L; Ferreri AJ; Panucci MG; Monfardini S; Ermani M;
    J Clin Oncol; 2004 May; 22(9):1598-604. PubMed ID: 15117981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.
    Hammond LA; Eckardt JR; Kuhn JG; Gerson SL; Johnson T; Smith L; Drengler RL; Campbell E; Weiss GR; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2004 Mar; 10(5):1645-56. PubMed ID: 15014015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
    DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP
    J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
    Jakacki RI; Hamilton M; Gilbertson RJ; Blaney SM; Tersak J; Krailo MD; Ingle AM; Voss SD; Dancey JE; Adamson PC
    J Clin Oncol; 2008 Oct; 26(30):4921-7. PubMed ID: 18794549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells.
    D'Atri S; Graziani G; Lacal PM; Nisticò V; Gilberti S; Faraoni I; Watson AJ; Bonmassar E; Margison GP
    J Pharmacol Exp Ther; 2000 Aug; 294(2):664-71. PubMed ID: 10900246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.
    Di Giannatale A; Dias-Gastellier N; Devos A; Mc Hugh K; Boubaker A; Courbon F; Verschuur A; Ducassoul S; Malekzadeh K; Casanova M; Amoroso L; Chastagner P; Zwaan CM; Munzer C; Aerts I; Landman-Parker J; Riccardi R; Le Deley MC; Geoerger B; Rubie H
    Eur J Cancer; 2014 Jan; 50(1):170-7. PubMed ID: 24021349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia.
    Rizzieri D; LoRusso S; Tse W; Khan K; Advani A; Moore J; Karsten V; Cahill A; Gerson SL
    Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):211-6. PubMed ID: 20511167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines.
    Bobola MS; Silber JR; Ellenbogen RG; Geyer JR; Blank A; Goff RD
    Clin Cancer Res; 2005 Apr; 11(7):2747-55. PubMed ID: 15814657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma.
    Kim KB; Hwu WJ; Papadopoulos NE; Bedikian AY; Camacho LH; Ng C; Hernandez IM; Frost AM; Jack MA; Hwu P
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):161-7. PubMed ID: 19002462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
    Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Rich JN; Gururangan S; Friedman AH; Bigner DD; Sampson JH; McLendon RE; Herndon JE; Walker A; Friedman HS
    Neuro Oncol; 2009 Oct; 11(5):556-61. PubMed ID: 19289491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors.
    Vera K; Djafari L; Faivre S; Guillamo JS; Djazouli K; Osorio M; Parker F; Cioloca C; Abdulkarim B; Armand JP; Raymond E
    Ann Oncol; 2004 Jan; 15(1):161-71. PubMed ID: 14679137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
    Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
    Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.